DrugPatentWatch Database Preview

Details for Patent: 5,364,620

« Back to Dashboard

Summary for Patent: 5,364,620

Title:	Controlled absorption diltiazem formulation for once daily administration
Abstract:	A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of the diltiazem from the pellet at a rate allowing controlled absorption thereof over a twenty four hour period following oral administration.
Inventor(s):	Geoghegan; Edward J. (Athlone, IE), Mulligan; Seamus (Athlone, IE), Panoz; Donald E. (Tuckerstown, BN)
Assignee:	Elan Corporation, Plc (Westmeath, IE)
Application Number:	07/921,459
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 5,364,620

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

International Patents Family Members for US Patent 5,364,620

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Spain	2194832
Ireland	833057
Switzerland	662507
Germany	3485023